Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma

Area of Science:

• Pediatric Oncology
• Medical Oncology
• Pharmacology

Background:

• Hepatoblastoma is a rare liver cancer primarily affecting children.
• Relapsed or refractory hepatoblastoma presents significant treatment challenges.
• Limited therapeutic options exist for advanced or recurrent hepatoblastoma.

Observation:

• Five children with relapsed or refractory hepatoblastoma received single-agent docetaxel.
• Dosing varied based on patient weight (100 mg/m(2) for >10 kg, 3.3 mg/kg for <10 kg).
• Treatment involved 1-hour infusions every 21 days.

Findings:

• One patient achieved complete remission of pulmonary metastases after two docetaxel courses.
• This patient remained well 10 years post-treatment, including whole-lung radiotherapy.
• Another patient showed a partial response, indicated by alpha-fetoprotein level changes.

Implications:

• Docetaxel exhibits potential anti-cancer activity in progressive hepatoblastoma.
• This case series suggests docetaxel as a viable option for future clinical studies.
• Further investigation is warranted to establish docetaxel's efficacy and safety in hepatoblastoma.